Labeling updates and warnings through October 2008 for adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), infliximab (Remicade), and rituximab (Rituxan).
FDA has notified the manufacturers of adalimumab (Humira, Abbott), certolizumab pegol (Cimzia, UCB), etanercept (Enbrel, Amgen/Wyeth), and infliximab (Remicade, Centocor) that the labeling for these drugs must be changed to strengthen warnings regarding the risk of development of opportunistic fungal infections. Although the prescribing information for these drugs already contains information about this risk, reports received by FDA have suggested that healthcare professionals are not consistently recognizing cases of histoplasmosis and other invasive fungal infections in patients treated with these agents, which could lead to delays in treatment. These treatment delays could result in death.
Genentech and Biogen Idec have notified healthcare professionals that a case of progressive multifocal leukoencephalopathy (PML) leading to death has been reported in a patient with rheumatoid arthritis who was treated with rituximab (Rituxan) in a long-term safety extension clinical trial. The prescribing information for rituximab has been updated to reflect this new information.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More